Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. by Kotecha, D et al.
Listen to this manuscript’s
audio summary by
Editor-in-Chief
Dr. Valentin Fuster on
JACC.org.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y VO L . 7 4 , N O . 2 3 , 2 0 1 9
ª 2 0 1 9 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A N
C O L L E G E O F C A R D I O L O G Y F OU N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .Impact of Renal Impairment on
Beta-Blocker Efﬁcacy in
Patients With Heart Failure
Dipak Kotecha, MD, PHD, MSC,a,b Simrat K. Gill, MD,a Marcus D. Flather, MD,c Jane Holmes, PHD,d Milton Packer, MD,e
Giuseppe Rosano, MD, PHD,f,g Michael Böhm, MD,h John J.V. McMurray, MD,i John Wikstrand, PHD,j
Stefan D. Anker, MD, PHD,k Dirk J. van Veldhuisen, MD,l Luis Manzano, MD,m Thomas G. von Lueder, MD, PHD,b,n
Alan S. Rigby, MSC,o Bert Andersson, MD, PHD,p John Kjekshus, MD, PHD,q Hans Wedel, PHD,r Frank Ruschitzka, MD,s
John G.F. Cleland, MD,t Kevin Damman, MD, PHD,l Josep Redon, MD,u Andrew J.S. Coats, MD, DSC,g
on behalf of the Beta-Blockers in Heart Failure Collaborative GroupABSTRACTISS
Fro
cu
Fa
Nu
Kin
Ins
Pis
Sa
jW
kD
Ca
UnBACKGROUND Moderate and moderately severe renal impairment are common in patients with heart failure and
reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy.
OBJECTIVES This study sought to investigate patient prognosis and the efﬁcacy of beta-blockers according to renal
function using estimated glomerular ﬁltration rate (eGFR).
METHODS Analysis of 16,740 individual patients with left ventricular ejection fraction <50% from 10 double-blind,
placebo-controlled trials was performed. The authors report all-cause mortality on an intention-to-treat basis, adjusted
for baseline covariates and stratiﬁed by heart rhythm.
RESULTS Median eGFR at baseline was 63 (interquartile range: 50 to 77) ml/min/1.73 m2; 4,584 patients (27.4%) had
eGFR 45 to 59 ml/min/1.73 m2, and 2,286 (13.7%) 30 to 44 ml/min/1.73 m2. Over a median follow-up of 1.3 years, eGFR
was independently associated with mortality, with a 12% higher risk of death for every 10 ml/min/1.73 m2 lower eGFR
(95% conﬁdence interval [CI]: 10% to 15%; p < 0.001). In 13,861 patients in sinus rhythm, beta-blockers reduced
mortality versus placebo; adjusted hazard ratio (HR): 0.73 for eGFR 45 to 59 ml/min/1.73 m2 (95% CI: 0.62 to 0.86;
p < 0.001) and 0.71 for eGFR 30 to 44 ml/min/1.73 m2 (95% CI: 0.58 to 0.87; p ¼ 0.001). The authors observed no
deterioration in renal function over time in patients with moderate or moderately severe renal impairment, no difference
in adverse events comparing beta-blockers with placebo, and higher mortality in patients with worsening renal
function on follow-up. Due to exclusion criteria, there were insufﬁcient patients with severe renal dysfunction
(eGFR <30 ml/min/1.73 m2) to draw conclusions. In 2,879 patients with atrial ﬁbrillation, there was no reduction in
mortality with beta-blockers at any level of eGFR.
CONCLUSIONS Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should
receive beta-blocker therapy even with moderate or moderately severe renal dysfunction. (J Am Coll Cardiol 2019;74:2893–904) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2019.09.059
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CI = conﬁdence interval
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
IPD = individual patient data
LVEF = left ventricular ejection
fraction
NNT = number needed to treat
RCT = randomized controlled
trials
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2894H eart failure (HF) is associated withnumerous comorbidities, of whichrenal dysfunction is both common
and of particular importance due to its
impact on mortality as well as on the use of
guideline-recommended therapies (1). Pa-
tients with HF have a higher incidence of
renal dysfunction due to shared pathophysi-
ological pathways and mutual risk factors. In
the Swedish HF registry (2), 51% of 47,716 pa-
tients with unselected HF had an estimated
glomerular ﬁltration (eGFR) of <60 ml/
min/1.73 m2, and in the CHARM (Candesartan
in Heart Failure: Assessment of Reduction
in Mortality and Morbidity) program, be-
tween 33% and 43% of patients had
eGFR <60 ml/min/1.73 m2 depending on HFphenotype (3). Impaired renal function is indepen-
dently associated with worse outcomes; in meta-
analyses of 57 studies including trials and cohorts in
HF, there was a 2-fold increase in the odds of death
comparing patients with and without renal dysfunc-
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prescription, dosage, maintenance, and possibly
effectiveness of therapies (5,6). Although common
in clinical practice, patients with renal dysfunction
have often been excluded from major clinical trials,
creating an evidence gap for many HF patients and a
discrepancy with clinical need. Those with moderate
renal dysfunction (eGFR 45 to 59 ml/min/1.73 m2)
and moderately severe renal dysfunction (eGFR 30
to 44 ml/min/1.73 m2) have a higher risk of adverseoutcomes and potentially more absolute beneﬁt
from HF therapy, but in addition have multiple
comorbidities that can have an impact on clinical
management. Previous analyses of beta-blockers in
patients with HF and renal dysfunction suggest that
efﬁcacy may be maintained at different levels of
baseline eGFR (7–10). However, the number of pa-
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2895We examined the effect of renal dysfunction on
outcomes in patients with HF and reduced ejection
fraction (HFrEF) using the totality of individual pa-
tient data (IPD) from the landmark, double-blind,
randomized controlled trials (RCTs) comparing beta-
blockers with placebo (11). The Beta-Blockers in
Heart Failure Collaborative Group is a multinational
project that has systematically harmonized clinical
trial data to improve management and outcomes in
patients with HF (12–15). In this study, we tested the
hypothesis that compared with placebo, beta-
blockers reduce mortality in patients with moderate
and moderately severe renal dysfunction. Further, we
looked at the prognostic impact of renal dysfunction
and associated variables, and how change in renal
function affects mortality.
METHODS
The Beta-Blockers in Heart Failure Collaborative
Group (Collaborative Systematic Overview of
Randomised Controlled Trials of Beta-Blockers in the
Treatment of Heart Failure [BB-meta-HF]) includes
the lead investigators from the relevant trials, with
support of the 4 pharmaceutical companies that
sponsored them (AstraZeneca, GlaxoSmithKline,
Merck Serono, and Menarini). This report was pre-
pared according to the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) IPD
guidance (16), and prospectively registered with
ClinicalTrials.gov (NCT00832442) and the PROSPERO
database of systematic reviews (CRD42014010012)
(17).
ELIGIBILITY AND SEARCH STRATEGY. Detailed
rationale and methods have previously been pub-
lished (11–13). Placebo-controlled trials were eligible
for inclusion if they recruited >300 patients, were not
confounded by investigation of other treatments, had
a planned follow-up of >6 months, and explicitly re-
ported mortality as an endpoint.
Eleven trials were included that account for
95.7% of eligible participants recruited in RCTs based
on a systematic review of published reports:
ANZ (Australia/New Zealand Heart Failure Study)
(18), BEST (Beta-Blocker Evaluation Survival Trial)
(19), CAPRICORN (Carvedilol Post-Infarct Survival
Control in LV Dysfunction Study) (20), CHRISTMAS
(Carvedilol Hibernating Reversible Ischaemia Trial:
Marker of Success Study) (21), CIBIS I (Cardiac Insuf-
ﬁciency Bisoprolol Study) (22), CIBIS-II (Cardiac
Insufﬁciency Bisoprolol Study II) (23), COPERNICUS
(Carvedilol Prospective Randomized Cumulative
Survival Study) (24), MDC (Metoprolol in Idiopathic
Dilated Cardiomyopathy Study) (25), MERIT-HF(Metoprolol CR/XL Randomised Intervention Trial in
Congestive Heart Failure) (26), SENIORS (Study of the
Effects of Nebivolol Intervention on Outcomes and
Rehospitalisation in Seniors with Heart Failure) (27);
and US-HF (U.S. Carvedilol Heart Failure Program)
(28).
All included studies had appropriate ethical
approval. Using the Cochrane Collaborations Risk of
Bias Tool, we established that each trial had a low risk
of bias (29).
DATA COLLECTION AND IPD INTEGRITY. A stan-
dardized data request form to obtain IPD from each
trial has been published, along with search results
and individual study demographics (11). IPD were
obtained for all 11 trials identiﬁed in the systematic
review, and data were extracted from original source
ﬁles provided by the pharmaceutical companies and
lead investigators. All data were cross-checked across
different trial databases and compared with pub-
lished reports. Discrepancies, inconsistencies, and
incomplete data were checked against original case
report forms and trial documentation to ensure IPD
integrity. All 11 trial databases were then harmonized
according to the standardized data request form to
match patient characteristics and outcomes across all
trials. Due to the small amount of missing data for
relevant covariates, imputation was not performed.
PARTICIPANTS. For this analysis, we included pa-
tients with a baseline creatinine available and left
ventricular ejection fraction (LVEF) <50% (the CIBIS I
trial was excluded due to a lack of renal function
data). Because we have previously identiﬁed a sig-
niﬁcant treatment interaction comparing sinus
rhythm and atrial ﬁbrillation/ﬂutter (AF) (12), patients
were stratiﬁed by heart rhythm on the baseline elec-
trocardiogram for treatment estimates. Those with
a missing electrocardiogram or paced rhythm
were excluded.
RENAL DYSFUNCTION AND RELATED VARIABLES.
Creatinine values were obtained for each enrolled
patient at baseline, the interim study visit and the
ﬁnal follow-up visit, where available. Renal function
was analyzed using eGFR calculated with the Modi-
ﬁcation of Diet in Renal Disease (MDRD) equation for
nonstandardized creatinine: 186  (serum creatinine
in mg/dl)1.154  (age)0.203  (0.742 if female)  (1.21
if African/African American) in ml/min/1.73 m2. eGFR
was categorized according to the National
Kidney Foundation staging: category 1, eGFR
$90 ml/min/1.73 m2 (normal); category 2, eGFR 60 to
89 ml/min/1.73 m2 (mildly decreased); category
3a, eGFR 45 to 59 ml/min/1.73 m2 (mildly to
moderately decreased); category 3b, eGFR 30 to
TABLE 1 Baseline Characteristics by eGFR Category for Patients in Sinus Rhythm
eGFR <30 ml/min/1.73 m2
(n ¼ 373)
eGFR 30–44 ml/min/1.73 m2
(n ¼ 1,825)
eGFR 45–59 ml/min/1.73 m2
(n ¼ 3,712)
eGFR 60–89 ml/min/1.73 m2
(n ¼ 6,405)
eGFR $90 ml/min/1.73 m2
(n ¼ 1,546)
eGFR, ml/min/1.73 m2 26 (24–28) 39 (36–42) 53 (50–57) 72 (66–79) 100 (94–109)
Age, yrs 71 (66–76) 70 (63–75) 67 (59–73) 61 (52–70) 54 (46–62)
Women 39.1 36.2 27.7 19.8 16.6
Years with HF diagnosis 4 (2–8) 4 (2–7) 3 (1–6) 2 (1–5) 2 (1–5)
Ischemic HF etiology 80.2 78.2 71.8 66.1 57.4
Prior myocardial infarction 64.8 67.4 62.4 56.0 49.4
Diabetes mellitus 43.0 31.9 24.1 22.1 23.4
NYHA functional class III/IV 80.5 71.8 67.3 60.1 70.3
LVEF, % 24 (20–31) 24 (20–31) 25 (20–32) 28 (21–33) 28 (22–33)
Heart rate, beats/min 79 (72–88) 80 (72–88) 80 (72–88) 80 (72–88) 80 (72–90)
Systolic BP, mm Hg 124 (110–140) 124 (110–140) 122 (110–138) 122 (110–138) 120 (110–137)
Diastolic BP, mm Hg 72 (65–80) 75 (68–80) 76 (70–81) 78 (70–83) 78 (70–84)
Body mass index, kg/m2 25 (23–29) 26 (23–29) 26 (24–30) 27 (24–30) 27 (24–30)
Any diuretic therapy 96.2 91.0 87.9 81.5 82.2
ACE inhibitor or ARB 92.2 93.0 95.4 95.1 95.6
Aldosterone antagonists 13.6 11.5 9.7 6.9 5.6
Digoxin 54.7 53.1 53.4 53.7 58.6
Values are median (interquartile range) or %.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BP ¼ blood pressure; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction;
NYHA ¼ New York Heart Association functional class.
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289644 ml/min/1.73 m2 (moderately to severely decreased);
and category 4 and 5 combined, eGFR<30ml/min/1.73m2
(severely decreased or kidney failure). We pre-deﬁned
patients with eGFR 30 to 59 ml/min/1.73 m2 as a group
of clinical interest, and worsening renal function as
20% or greater reduction in eGFR between baseline
and follow-up. When used as a continuous variable in
interaction analyses, the lowest and highest 1% of
eGFR values were excluded to avoid leverage of
extreme results. Anemia was classiﬁed according
to the World Health Organization deﬁnition
(hemoglobin <13.0 g/dl in men and <12.0 g/dl in
women), and proteinuria was deﬁned as 1þ on a
dipstick or $30 mg/dl.
OUTCOME. The outcome for this analysis was all-
cause mortality, which included additional deaths
reported after the censor date for 7 studies
(18–20,24,25,27,28). There were no patients with
missing vital status.
STATISTICAL ANALYSIS. A statistical analysis plan
was generated and ﬁnalized by the Collaborative
Group in advance of data analysis. Summary results
are presented as percentages, or median and inter-
quartile range (displayed as 25th to 75th quartiles).
Group comparisons were made using the Kruskal
Wallis nonparametric rank test. Fractional poly-
nomials were used to ﬁnd the best transformation of
eGFR in adjusted analysis, including nonlinear re-
lationships (for sinus rhythm, the best ﬁt was theinverse square root, and for AF the inverse
squared eGFR).
All analyses of beta-blockers versus placebo fol-
lowed the principle of intention to treat. Outcomes
were analyzed using a Cox proportional hazards
regression model stratiﬁed by study and grouped by
heart rhythm and eGFR category. This is a 1-stage
ﬁxed-effects approach and assumes that all trials are
estimating a common treatment effect with baseline
hazards that vary across studies. Hazard ratios (HRs)
and 95% conﬁdence intervals (CIs) are presented,
along with corresponding p values. We pre-speciﬁed
adjustment in Cox models for baseline age, sex,
LVEF, history of myocardial infarction, systolic blood
pressure, heart rate, use of angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers,
and diuretic therapy. Only a minority of patients were
followed for an extended period, and therefore data
were censored at 1,200 days (3.3 years) from
randomization.
Effect modiﬁcation was assessed using p values
from interaction terms ﬁtted in the multivariable
models. The interactions of continuous eGFR with
mortality or beta-blocker efﬁcacy were assessed using
cubic splines in the Cox model and the Royston-
Parmar ﬂexible parametric survival model (30).
There was no evidence of violation of the propor-
tional hazards assumption in any multivariable model
as determined by Schoenfeld residuals. Kaplan-Meier
plots were used to graph the pooled, unadjusted data
FIGURE 1 Prognostic Impact of Renal Dysfunction
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Association of baseline renal function with all-cause mortality and cause of death. Includes patients with sinus rhythm and atrial ﬁbrillation/
ﬂutter. CV ¼ cardiovascular; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure.
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2897for eGFR/treatment groups, with log-rank p values for
comparison. For worsening eGFR, analysis time
began on the date of the ﬁnal eGFR measurement
(hence excluding any patients who had died, with-
drawn consent, or were lost to follow-up before their
repeat eGFR), and ends 2 years after this date.
Pre-deﬁned sensitivity analyses in patients with
eGFR 30 to 59 ml/min/1.73 m2 were: 1) additional
multivariable adjustment for diabetes, body mass
index, New York Heart Association (NYHA) functional
class (I/II vs. III/IV), and use of digoxin or aldosterone
antagonists; 2) effect estimate in patients withLVEF <35% compared with 35% to 49%; and
3) exclusion of CAPRICORN (the only post-infarct
trial) and BEST (utilizing a pharmacologically
distinct beta-blocker). We also performed sensitivity
analyses using all available eGFR measurements for
interaction analyses, rather than just the central 99%.
Heterogeneity for pooled outcomes was assessed us-
ing the I2 statistic from a ﬁxed-effects 2-stage model.
We performed post hoc analyses: 1) according to dose
achieved at interim follow-up; 2) to assess the rela-
tionship between proteinuria and worsening renal
function; and 3) using the CKD-EPI (Chronic Kidney
TABLE 2 Beta-Blockers Versus Placebo According to Baseline Renal Function in Sinus Rhythm
eGFR
<30 ml/min/1.73 m2 30–44 ml/min/1.73 m2 45–59 ml/min/1.73 m2 60–89 ml/min/1.73 m2 $90 ml/min/1.73 m2
Number of patients with
complete data*
372 1,817 3,680 6,372 1,543
Number of deaths (%) 111 (29.8) 405 (22.3) 592 (16.1) 834 (13.1) 168 (10.9)
Hazard ratio for beta-blockers versus placebo 1.28 0.71 0.73 0.66 0.64
Hazard ratio 95% conﬁdence interval 0.87 to 1.91 0.58 to 0.87 0.62 to 0.86 0.57 to 0.76 0.47 to 0.88
p value 0.35 0.001 <0.0001 <0.0001 0.006
Absolute risk reduction† 2.4% 4.7% 4.0% 4.4% 4.7%
Absolute risk reduction 95% conﬁdence
interval
11.7% to 6.9% 0.8% to 8.5% 1.6% to 6.5% 2.7% to 6.1% 1.5% to 7.8%
NNT/NNH NNH 41.5 NNT 21.4 NNT 24.7 NNT 22.7 NNT 21.5
*Including baseline adjustment variables: eGFR, age, sex, left ventricular ejection fraction, history of myocardial infarction, systolic blood pressure, heart rate, use of angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers, and diuretic therapy. †Based on crude mortality rates for all patients.
eGFR ¼ estimated glomerular ﬁltration rate; NNH ¼ number needed to harm; NNT ¼ number needed to treat.
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2898Disease Epidemiology Collaboration) eGFR calculator.
A 2-tailed p value of 0.05 was considered statistically
signiﬁcant. Analyses were performed on Stata version
14.2 software (StataCorp, College Station, Texas) and
R version 3.2.1 (R Core Team, Vienna, Austria).
RESULTS
A total of 16,740 HF patients were included from 10
RCTs (Online Figure 1). Median age was 65 years
(25th to 75th centiles 55 to 72 years), 23% were
women, and median LVEF was 27% (21% to 33%).
Baseline median eGFR was 63 ml/min/1.73 m2. A to-
tal of 1,781 patients (10.6%) had an eGFR >90 ml/
min/1.73 m2, 7,641 (45.6%) 60 to 89 ml/min/1.73 m2,
4,584 (27.4%) 45 to 59 ml/min/1.73 m2, and 2,286
(13.7%) 30 to 44 ml/min/1.73 m2. Only 448 patients
(2.7%) had an eGFR <30 ml/min/1.73 m2, reﬂecting
the exclusion criteria for several trials (Online
Table 1). Patients in sinus rhythm (n ¼ 13,861) had
better renal function at baseline than those with AF
(n ¼ 2,879); 64 ml/min/1.73 m2 compared with 60 ml/
min/1.73 m2, with 42.9% versus 48.9% of patients
with eGFR <60 ml/min/1.73 m2, respectively. Other
factors associated with more advanced renal
dysfunction were older age and female sex, a longer
duration of HF, an ischemic etiology, and concomi-
tant diabetes (Table 1 shows data for sinus rhythm,
and Online Table 2 for AF).
IMPACT OF RENAL DYSFUNCTION ON MORTALITY IN
HFrEF. During a median follow-up of 1.3 years (0.8 to
1.9 years), eGFR was associated with all-cause mor-
tality independent of other measured prognostic
variables, with a 12% increase in the hazard of death
for every 10 ml/min lower eGFR (95% CI: 10% to 15%;p < 0.001). Mortality was particularly high for pa-
tients with more severe renal dysfunction, and their
cause of death was more often due to progressive
heart failure (Figure 1, Online Table 3).
In the subset of patients with hemoglobin values,
anemia was associated with higher mortality (HR: 1.35
compared with no anemia, 95% CI: 1.22 to 1.50;
p < 0.001; n ¼ 9,906). This was evident at all levels of
cardiorenal dysfunction, except for patients with
eGFR <30 ml/min/1.73 m2 (Online Figure 2). Protein-
uria at baseline was also independently associated
with higher mortality (HR: 1.32 compared with no
proteinuria, 95% CI: 1.02 to 1.70; p ¼ 0.034; n ¼ 3,081).
The largest prognostic impact of proteinuria was seen
in patients with eGFR $90 ml/min/1.73 m2 (Online
Figure 2); in this group, the death rate was 12.3%
without proteinuria and 28.6% with proteinuria
(adjusted p ¼ 0.032).
BETA-BLOCKER EFFICACY ACCORDING TO RENAL
FUNCTION AT BASELINE. In 13,861 patients in sinus
rhythm, beta-blockers reduced mortality across all
patients (HR: 0.71; 95% CI: 0.66 to 0.78; p < 0.0001),
including those with moderate and moderately se-
vere renal dysfunction (Table 2). The adjusted HR for
beta-blockers versus placebo in sinus rhythm was
0.73 for eGFR 45 to 59 ml/min/1.73 m2 (0.62 to 0.86;
p < 0.001), and 0.71 for eGFR 30 to 44 ml/min/1.73 m2
(0.58 to 0.87; p ¼ 0.001). Absolute risk reductions and
number needed to treat (NNT) to prevent 1 death
were 4.0% (NNT ¼ 25) and 4.7% (NNT ¼ 21), respec-
tively. There were insufﬁcient numbers of patients
with eGFR <30 ml/min/1.73 m2 to be certain of any
beneﬁt or harm from beta-blocker therapy (95% CI:
0.87 to 1.91). We detected an interaction between
beta-blocker efﬁcacy and eGFR in sinus rhythm
CENTRAL ILLUSTRATION Efﬁcacy of Beta-Blockers According to Baseline Renal Function in Sinus Rhythm
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Kotecha, D. et al. J Am Coll Cardiol. 2019;74(23):2893–904.
All-cause mortality comparing beta-blockers versus placebo in patients with sinus rhythm at baseline. Top panel shows a ﬂexible parametric survival spline plot across
the range of continuous renal function. Interaction p ¼ 0.021 for the central 99% of eGFR values (p ¼ 0.062 in a sensitivity analysis that includes the extremes of
eGFR). Lower panels show Kaplan-Meier survival plots for categorical renal groups, with p values derived from log-rank tests and adjusted Cox regression (Table 2).
eGFR ¼ estimated glomerular ﬁltration rate.
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2899(p ¼ 0.021), but with weak effect and only at the
lowest end of the eGFR range (Central Illustration). In
a sensitivity analysis that included all patients,
including the extremes of eGFR, the interaction
p value was 0.062.
The efﬁcacy of beta-blockers in patients with si-
nus rhythm and moderate or moderately severe
renal impairment was not affected by the presence
of either anemia or proteinuria (interaction p ¼ 0.69
and p ¼ 0.24), or by LVEF or additional adjustment
(Online Table 4). In 2,879 patients with AF at
baseline, there was no signiﬁcant reduction in
mortality with beta-blockers in any category of
eGFR, and no interaction of beta-blocker efﬁcacy
with continuous eGFR (p for interaction ¼ 0.18)
(Table 3, Figure 2).CHANGE IN RENAL FUNCTION OVER TIME, DOSE OF
THERAPY, AND ADVERSE EVENTS. Only a small drop
in mean eGFR was noted overall from baseline to the
last available measurement: 2.0 ml/min/1.73 m2 lower
eGFR after a median of 1.2 years for 7,420 surviving
patients in sinus rhythm (SD 15.2). In 3,179 patients
with either moderate or moderately severe renal
impairment at baseline, there was an increase of
1.3 ml/min/1.73 m2 (SD 13.1). We observed little dif-
ference between patients randomized to beta-
blockers or placebo (Figure 3, Online Table 5).
Worsening renal function of 20% or greater during
follow-up was observed in 1,342 (18.1%) of patients in
sinus rhythm, and was associated with a 28% higher
adjusted risk of death during the subsequent 2 years
(95% CI: 9% to 49%; p ¼ 0.002; n ¼ 4,725). The
TABLE 3 Beta-Blockers Versus Placebo According to Baseline Renal Function in AF
eGFR
<30 ml/min/1.73 m2 30–44 ml/min/1.73 m2 45–59 ml/min/1.73 m2 60–89 ml/min/1.73 m2 $90 ml/min/1.73 m2
Number of patients with
complete data*
74 458 869 1,230 235
Number of deaths (%) 24 (32.4) 137 (29.9) 172 (19.8) 207 (16.8) 36 (15.3)
Hazard ratio for beta-blockers
versus placebo
0.58 0.83 1.08 0.97 0.88
Hazard ratio 95% conﬁdence interval 0.21–1.63 0.58–1.19 0.80–1.47 0.74–1.29 0.44–1.75
p value 0.32 0.32 0.59 0.86 0.79
*Including baseline adjustment variables: eGFR, age, sex, left ventricular ejection fraction, history of myocardial infarction, systolic blood pressure, heart rate, use of angiotensin converting enzyme inhibitors
or angiotensin receptor blockers, and diuretic therapy.
AF ¼ atrial ﬁbrillation; eGFR ¼ estimated glomerular ﬁltration rate.
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2900corresponding mortality increase was 46% for the
subset of patients with combined moderate or
moderately severe renal impairment at baseline
(95% CI: 14% to 87%; p ¼ 0.002; n ¼ 2,175) (Figure 3).
In patients with sinus rhythm and moderate or
moderately severe renal impairment, 77% managed to
reach one-half of the target dose of beta-blocker or
greater (compared with 80% with eGFR 60 to 89 ml/
min/1.73 m2 and 84% with eGFR $90 ml/min/1.73 m2)
(Online Table 6). These patients had substantially
better prognosis than those at lower dose levelsFIGURE 2 Efﬁcacy of Beta-Blockers According to Baseline Renal Fun
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extremes of eGFR). AF ¼ atrial ﬁbrillation; eGFR ¼ estimated glomerula(Online Figure 3); however, the same pattern was also
seen in patients randomized to placebo. Across both
sinus rhythm and AF, discontinuation of beta-
blockers was similar to that seen with placebo in pa-
tients with moderate and moderately severe renal
dysfunction. This was the case for all adverse events
leading to therapy discontinuation, and also those
speciﬁcally related to renal impairment (Online
Table 7). Overall, discontinuation rates for both
beta-blockers and placebo were higher in those with
more advanced renal dysfunction.ction in AF
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FIGURE 3 Change in Renal Function and Impact on Mortality in Sinus Rhythm
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Left panel shows the change in renal function in patients with sinus rhythm according to renal function groups at baseline. Mean values and 95% conﬁdence intervals
are depicted only for 5,469 patients with data available at all time-points: baseline, interim visit at a median of 0.5 years from randomization (interquartile range: 0.4
to 0.7), and ﬁnal visit at a median of 1.5 years from randomization (interquartile range: 1.0 to 2.1). Right panel shows a Kaplan-Meier survival plot for patients in sinus
rhythm with moderate or moderately severe renal impairment according to whether eGFR worsened by $20% from baseline to the last available measurement
(log-rank p value <0.0001). Analysis time begins at the date of the last eGFR and therefore excludes patients that died or were lost to follow-up before this visit
(median 1.2 years after randomization). eGFR ¼ estimated glomerular ﬁltration rate.
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2901DISCUSSION
Renal impairment is often a barrier in clinical practice
for the commencement and up-titration of guideline-
recommended HFrEF therapy (5,6). Most patients
with HFrEF have some degree of renal impairment,
yet many randomized trials have excluded those with
signiﬁcant renal dysfunction, leading to concerns by
clinicians about efﬁcacy and safety. Using robust and
high-quality data from the landmark beta-blocker
trials, we have demonstrated with sufﬁcient sample
size that beta-blockers are effective in reducing
mortality in patients with HFrEF and sinus rhythm,
even in those with moderately severe renal dysfunc-
tion (as low as an eGFR of 30 to 44 ml/min/1.73 m2).
Despite higher rates of comorbidities, the absolute
beneﬁt in this group was similar to patients with
eGFR >90 ml/min/1.73 m2. Discontinuation due to
adverse events was the same for both beta-blockersand placebo in these double-blind trials and renal
function did not appear to worsen even in those with
kidney dysfunction at baseline. These results suggest
that renal impairment should not obstruct the pre-
scription of beta-blockers in patients with HFrEF.
PROGNOSTIC IMPLICATIONS OF RENAL DYSFUNCTION,
ANEMIA, AND PROTEINURIA. The prognosis for pa-
tients with HFrEF has many determinants, and renal
dysfunction is a well-known contributor to adverse
outcomes (4). Our data highlight the different pattern
of patient prognosis according to the severity of renal
dysfunction, with a complete reversal in sudden
cardiac death and death due to progressive HF
comparing preserved and severe renal dysfunction.
Whereas anemia was associated with higher mortality
across most patients (with the exception of
eGFR <30 ml/min/1.73 m2, where renal replacement
therapy and erythropoietin come into play [31]),
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2902proteinuria had the most marked impact in those with
preserved renal function. Proteinuria at baseline was
not associated with a higher chance of worsening
renal function (post hoc p ¼ 0.61) and so could be a
useful independent marker of elevated risk (despite
apparently normal renal function), or even of insuf-
ﬁcient HF therapy (32).
HF TREATMENT IN PATIENTS WITH RENAL IMPAIRMENT.
Our results highlight the importance of appropriate
HFrEF therapy for all patients, especially those with
renal insufﬁciency who could beneﬁt the most. Sub-
group analyses from both the Val-HeFT (Valsartan in
Heart Failure Trial) (N ¼ 2,346) and the RALES (Ran-
domized Aldactone Evaluation Study; N ¼ 792) trials
showed that the beneﬁt of valsartan and spi-
ronolactone were consistent in patients above and
below an eGFR of 60 ml/min/1.73 m2 (33,34). In more
recent trials, no interactions have been noted for
renal impairment using this same eGFR cutoff for
eplerenone (n ¼ 912) or sacubitril-valsartan
(n ¼ 3,061) (35,36). However, because the median
eGFR in clinical practice is often around 60 ml/
min/1.73 m2, it could be argued that a more realistic
cutpoint is required to reassure clinicians about the
safety and efﬁcacy of therapy. Unfortunately, data
speciﬁcally in patients with moderately severe renal
dysfunction are limited (37). Subgroup analysis from
the MERIT-HF trial (8), as well as the CIBIS-II (10) and
SENIORS (9) trials, suggested potential beneﬁt from
beta-blockers in those with eGFR <45 ml/min/1.73 m2,
hence the need for this analysis that included all of
these RCTs and more. HFrEF patients with severe
renal dysfunction or kidney failure have largely been
excluded from RCTs. One exception was a small trial
in 114 dialysis patients, where carvedilol was found to
improve clinical status (38). Although we have pooled
data from 10 placebo-controlled trials of beta-
blockers, only 448 patients (2.7%) had an
eGFR <30 ml/min/1.73 m2. Event rates were high, but
due to the restricted sample size, we are unable to
comment on the true efﬁcacy of beta-blockers in this
patient group; new RCTs are clearly warranted to
address this knowledge gap.
WORSENING RENAL FUNCTION. Clinicians are often
concerned about the potential for worsening renal
function during initiation or up-titration of HF ther-
apy. We show that beta-blockers do not lead to any
overall deterioration in renal function in those
with existing impairment. The results we present
on worsening renal function (not caused by initiation
of renin-angiotensin-aldosterone system inhibitors)
are similar to other studies showing that deterioration
of function is associated with higher mortality (39).Our data suggest that preservation of renal function
may be an important management goal. However,
post-randomization variables such as repeated eGFR
measurement should be judged carefully even in
double-blind trials, as they are prone to the same
biases as observational data. Achieving target dosage
remains an essential task for HF teams. We demon-
strate that this is achievable for the majority of patients
with renal dysfunction, even those with moderately se-
vere impairment. However, dose is a complicated vari-
able also affected by physician- and patient-level biases,
as highlighted by the marked difference in mortality
according to the placebo dose attained.
PATIENTS WITH HF AND CONCOMITANT ATRIAL
FIBRILLATION. We pre-speciﬁed stratiﬁcation of an-
alyses by heart rhythm due to signiﬁcant interactions
with beta-blocker efﬁcacy (12) and a marked differ-
ence in the association of heart rate with mortality
comparing sinus rhythm with AF (14). The lack of
beneﬁt from beta-blockers regardless of eGFR in pa-
tients with AF was therefore unsurprising. Similar to
sinus rhythm, we show that renal dysfunction in pa-
tients with AF is associated with more high-risk fea-
tures, but the majority of patients can reach
appropriate dosage. Higher rates of renal dysfunction
in AF and worse prognosis across all eGFR categories
compared with sinus rhythm demonstrate the need
for improved multidisciplinary management of
concomitant AF and HF (40).
STUDY STRENGTHS AND LIMITATIONS. The current
analysis uses IPD from 10 landmark, placebo-
controlled trials. An extensive period of additional
data collation was performed from original case
report forms, including events not originally re-
ported, with data cleaning and harmonization ac-
cording to a published design (11). Each of the trials
had different inclusion and exclusion criteria,
although treatment effects were similar for eGFR 30
to 59 ml/min/1.73 m2 even when the 2 more unique
trials were excluded. Exclusion of these 2 RCTs led to
no signiﬁcant heterogeneity in treatment effect in the
remaining studies (Online Table 4). Due to the large
sample size, we were able to test the interaction of
beta-blocker efﬁcacy across the range of continuous
eGFR. We conﬁrmed nonlinearity and used fractional
polynomial transformations to obtain optimal model
ﬁtting in sinus rhythm and AF. However, despite us-
ing nonlinear approaches, splines, and ﬂexible para-
metric models, interaction tests have relatively
low power, and we may have missed a clinically sig-
niﬁcant interaction in small subgroups. The MDRD
formula was used for primary estimation of kidney
function as the CKD-EPI calculation requires
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Beta-blocker
therapy reduces mortality in patients with heart failure and
reduced ejection fraction in sinus rhythm, including those with
moderate (eGFR 45 to 59 ml/min/1.73 m2) and moderately
severe (eGFR 30 to 44 ml/min/1.73 m2) renal dysfunction.
TRANSLATIONAL OUTLOOK: Further research is needed in
patients with atrial ﬁbrillation, in whom beta-blockers are not
associated with lower mortality rates, and those with severe
renal impairment (eGFR <30 ml/min/1.73 m2), about whom there
are limited data.
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2903standardized creatinine measurements, although we
saw no difference in treatment effects in a post hoc
analysis. Due to our prior ﬁndings (15), we included
patients with both mid-range and reduced LVEF in
the current study and demonstrated similar efﬁcacy
from beta-blockers regardless of baseline (reduced)
LVEF. As discussed, any analysis of post-
randomization variables (follow-up eGFR, dose, and
so on) should be considered exploratory and may be
affected by regression toward the mean, and selection
or survivor bias. We have deliberately not addressed
hospital admissions in this paper, due to concerns
that kidney disease can itself inﬂuence the likelihood
of a physician admitting a patient, lead to withdrawal
of other heart failure therapy, and confound the as-
sociation with adverse outcomes. Finally, this a
retrospective analysis, and further new RCTs should
be encouraged in view of the commonality of renal
dysfunction in HF.
CONCLUSIONS
Combining double-blind, individual patient-level
data has provided a sufﬁcient sample size to conﬁrm
the efﬁcacy of beta-blockers in heart failure patients
with reduced ejection fraction, sinus rhythm and
renal dysfunction, including those with eGFR 30 to
44 ml/min/1.73 m2, the lowest range of eGFR tested in
large placebo-controlled trials.
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